We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the wake of a long-awaited court decision that dismissed the country's fee-based pharmacy dispensing system, South Africa's government has re-appointed the members of its Pricing Committee.
New market data indicated that the size of Brazil's generics market
has increased by four times since 2001, when a law recognising the products as a distinct entity was introduced.
Serbia and Montenegro's Ministry of Health has met with the country's
drugmakers in order to discuss the creation of a national medicines policy to improve drug quality, consumer access and distribution.
Panacos Pharmaceuticals Inc. (PANC.O: Quote, Profile, Research) on Thursday said it priced a public offering of 8.25 million shares at $10.50 per share.
TOPIGEN Pharmaceuticals Inc., a developer of multi-targeted respiratory products that inhibits major pathways involved in cellular recruitment and inflammation, today announced that it has raised CA$6 million in a second closing of its Series B round of financing.
Hoe Pharmaceuticals Sdn Bhd, unofficially crowned by local medical practitioners as the 'King of Creams,' will open two more plants, one each in China and Australia in the next two years, its chief executive officer Lee Boon Kian said.
Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, today announced that it has acquired all assets belonging to Arthron Ltd. Pty. (Arthron), a subsidiary of Prima Biomed Ltd. (Prima).
XOMA Ltd. (Nasdaq:XOMA) today announced that it has expanded its existing non-exclusive, worldwide license to Crucell N.V. (Euronext, Nasdaq: CRXL) under XOMA's bacterial cell expression (BCE) technology to improve Crucell's position to perform phage display in the field of infectious disease with third party collaborators.
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has granted approval of REMICADE (R) (infliximab) for the treatment of moderate to severe plaque psoriasis.